+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 65Years +
All Genders
ID06042569

Evaluating Dose-Reduced Docetaxel Plus Cyclophosphamide Versus Standard Dose for Vulnerable Older Women With Early-Stage HER2-Negative Breast Cancer

Led by City of Hope Medical Center · Updated on 2026-11-04

174

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how dose-reduced docetaxel combined with cyclophosphamide works compared to standard doses in treating older women with early-stage stage I-III HER2-negative breast cancer who may be vulnerable to treatment side effects. This phase II trial aims to find out if reducing the docetaxel dose can improve treatment tolerance while effectively managing the cancer. Participants are randomly assigned to one of two groups. One group receives dose-reduced docetaxel intravenously over 60 minutes plus cyclophosphamide intravenously over 30 minutes on day 1 of each 21-day cycle, repeated for 4 cycles if there is no disease progression or unacceptable toxicity. The other group receives standard doses of the same drugs on the same schedule. After completing treatment, participants are followed up at 30 days and then at least twice a year for 2 years. During the study, participants undergo various assessments including questionnaires on symptoms, function, and health status at multiple time points up to 24 months after treatment. Researchers monitor the relative dose intensity, treatment success, patient-reported toxicities, satisfaction, adverse events, and survival outcomes including invasive disease-free survival and overall survival. Follow-up visits help track long-term effects and safety over several years.

CONDITIONS

Brief Title

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

Research Team

T

Thanh Nga Doan, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here